InhaTarget Therapeutics

TLDR

InhaTarget Therapeutics develops innovative inhalation formulations for severe respiratory diseases, with initial focus on lung cancer treatment.

Overview

InhaTarget Therapeutics is a spin-off from the University of Brussels (ULB) dedicated to early development and clinical validation of innovative pulmonary disease treatments via inhalation. The company brings together expertise in drug formulation, inhalation delivery, immunology, preclinical development, and clinical operations, aiming to improve existing molecules through novel treatment modalities.